Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Paladin buys struggling CNS company Allon Therapeutics for $Cdn900k

Executive Summary

Paladin Labs Inc. (builds its portfolio through in-licensing) has paid $Cdn900k ($866k) in cash to acquire formerly publicly traded Allon Therapeutics Inc. (had been developing CNS candidates). The transaction was conducted as a result of Allon’s proposed bankruptcy filing in Canada, and the company will immediately disperse the funds it receives to its creditors.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Payment Includes Cash

Related Companies